Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_995c71109762882f3cc26e74d8d61acf |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2011-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4f12b29b572f90d35b2b5921e1a11d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a80d0150452f404c66264724b22399ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba85a59a53b1f636efa625c189008f72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a6fb718501f257d4fe7c66cea41b50a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6017bf005ddd1b3952730c510615410 |
publicationDate |
2011-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2011116760-A |
titleOfInvention |
Use of antagonist anti-CD40 monoclonal antibodies for the treatment of chronic lymphocytic leukemia |
abstract |
The present invention provides a method for the treatment of chronic lymphocytic leukemia using an antagonist anti-CD40 monoclonal antibody. A therapeutic method is provided for treating a subject for chronic lymphocytic leukemia. The method includes administering to a patient in need thereof a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof. An antagonist anti-CD40 antibody or antigen-binding fragment thereof does not have significant agonist activity, but exhibits antagonist activity when the antibody binds to a CD40 antigen on human CD40-expressing cells. The antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof advantageously inhibits the proliferation and / or differentiation of chronic lymphocytic leukemia cells that express human CD40. [Selection figure] None |
priorityDate |
2003-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |